Alzheimer's disease features amyloid-beta plaques and tau tangles, driving neuronal loss and cognitive decline.
Alzheimer's disease features amyloid-beta plaques and tau tangles, driving neuronal loss and cognitive decline. Stem-cell approaches address several pathways: placental mesenchymal stem cells are studied for neuroprotection — secreting anti-inflammatory and growth factors that may slow neuronal death — while exosomes derived from stem cells are explored as carriers for therapeutic molecules across the blood-brain barrier and as modulators of amyloid and tau biology. The rationale builds on evidence that stem-cell products reduce neuroinflammation and may support hippocampal neuroplasticity. Reversing established pathology and achieving adequate brain delivery remain unsolved; early trials are small and heterogeneous, with uncertain durability.
| עלות מעריכה · בולגריה (EU) | €3,000–€8,000 |
|---|---|
| טווח עלויות השוק הגלובלי | €18,900–€21,000 (bookinghealth.com) |
| סוגי התאים העיקריים שנחקרו | MSCs from Amniotic Membrane, Exosomes |
| סטטוס אישור | ניסיוני |
| ניסויים רשומים (ClinicalTrials.gov) | 41 · 9 recruiting now |
For the clinic's own description, see how Stem Plus describes its Alzheimer's Disease programme ↗.
Forty-one registered trials and 9 recruiting studies investigate stem-cell therapy in Alzheimer's. Small cohorts describe modest cognitive-score changes over 6–12 months; most are uncontrolled. Some show shifts in cerebrospinal-fluid or PET amyloid/tau markers, with less consistent functional gains. No trial has prevented decline or shown reversal of neuronal loss. Approved amyloid-targeting antibodies (lecanemab, aducanumab) show modest slowing of early decline — stem-cell benefit is not proven to match them.
Depending on assessment, a Alzheimer's Disease protocol may draw on:
Indicative European costs are roughly €3,500–€7,000 per course; exosome-based protocols can reach €5,000–€8,000 due to manufacturing complexity. Pre/post neuroimaging (MRI, PET) adds further expense, and multi-dose protocols are common. For context, approved Alzheimer's drugs range from inexpensive symptomatic agents to costly antibody infusions — the stem-cell figure is indicative and less evidence-backed.
Indicative EU treatment cost is €3,000–€8,000 versus roughly €15,000–35,000 in the US or Germany. Build your real all-in total with the cost calculator, see the Alzheimer's Disease cost-by-country breakdown, or compare the best countries for Alzheimer's Disease →
Before booking, check safety & regulation, the recovery climate, אם אתה עשוי להיות מועמד, and which cell type fits Alzheimer's Disease.
שאלות תשובות מחלת אלצהיימר מלאות → · פירוט עלויות מחלת אלצהיימר →
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Useful tools & guides: האם אני מועמד? · איזה סוג תאים? · Types of clinics & best countries · מחשבון עלויות
בדוקה רפואית על ידי צוות העריכה של StemCellAtlas עם Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) של קליניקת השותף Stem Plus (סופיה), כנגד הנחיות ISSCR, FDA ו-EMA. Educational information, not medical advice; figures indicative.
רפואה רגנרטיבית מאושרת GMP בלב האיחוד האירופי — החל מ-3,000–8,000 יורו, חלק קטן ממחירי ארהב או גרמניה. פרוטוקולים מותאמים אישית למטופלים מ-50+ מדינות.
בדיקה רפואית חינם